Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older

This study evaluates the safety of the quadrivalent subunit influenza vaccine following its post-marketing widespread use in individuals aged 3 years and older, aiming to assess the occurrence of very rare adverse reactions (with an incidence rate of \<0.01%).

NCT Number	NCT07332689
Lead Sponsor	Ab&B Bio-tech Co., Ltd.JS Collaborators: Jiangsu Provincial Academy of Preventive Medicine, Hubei Provincial Center for Disease Control and Prevention, Shandong Province Centers for Disease Control and Prevention, Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Gansu Provincial Center for Disease Control and Prevention, Guangdong Provincial Institute of Biological Products And Materia Medica, Qinghai Provincial Center for Disease Control and Prevention
Conditions	Influenza Vaccine
Enrollment	42,881 participants
Start Date	2023-10-30
Primary Completion	2025-04-28 (estimated)
Study Completion	2025-04-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-12